HIV Protease Inhibitors

06/07/1996 - "The most active diastereomer of the sulfonamide-containing pyrone XVIII (Ki = 0.5 nM) shows improved antiviral activity (IC50 = 0.6 nM) and represents an example of a new design direction for the discovery of more potent non-peptidic HIV protease inhibitors as potential therapeutic agents for the treatment of HIV infection."
12/01/2014 - "The development of HIV protease inhibitors (HIV PIs) has been one of the most significant advances of the past two decades in controlling HIV infection. "
08/01/2012 - "HIV protease inhibitors are essential components of most recommended treatment regimens for HIV infection. "
11/01/2010 - "HIV protease inhibitors (HIV PI) reduce morbidity and mortality of HIV infection but cause multiple untoward effects. "
06/07/2010 - "The development of HIV protease inhibitors (PIs) has been one of the most significant advances of the past decade in controlling HIV infection. "

10/01/1998 - "Recent clinical trials have demonstrated that HIV protease inhibitors are useful in the treatment of AIDS. "
10/01/2001 - "We performed a study of the effects of HIV protease inhibitors (PIs) on the incidence of relapse and time to death in AIDS patients with CMV-R treated with anti-CMV therapy. "
09/07/2000 - "Recent results from human clinical trials have established the critical role of HIV protease inhibitors in the treatment of acquired immune-deficiency syndrome (AIDS). "
02/01/2010 - "HIV-PIs (HIV protease inhibitors) have proved to be of great benefit for the millions of people suffering from AIDS. "
12/01/2009 - "The advent of HIV protease inhibitors has greatly extended the life span of AIDS patients. "

06/01/2000 - "HIV protease inhibitors have proven remarkably effective in treating HIV-1 infection. "
09/01/2013 - "The development of HIV protease inhibitors more than two decades ago heralded a new era in HIV care, changing the infection from universally fatal to chronic but controllable. "
01/01/2010 - "Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors. "
11/01/2009 - "We found that HIV protease inhibitors (PIs) reduced virion endocytosis strongly in monocyte-derived immature (i) DCs contacting HIV-1-infected cells, and that this phenomenon led to dramatically impaired trans-infection activity. "
10/20/2006 - "Both have been proved to be human immunodeficiency virus (HIV) protease inhibitors and have substantially reduced the morbidity and mortality associated with HIV-1 infection. "

07/01/2002 - "The lower rates of oropharyngeal candidiasis observed in individuals receiving antiretroviral combination therapy could reflect not only an improvement in the immune system but also direct inhibition of Candida Saps by HIV protease inhibitors. "
07/01/2001 - "In future, derivatives of HIV protease inhibitors, being more specific for the fungal Saps, may form an alternative in the treatment of mucosal candidiasis insensitive to currently available antimycotics."
07/01/2001 - "In conclusion, inhibition of Saps by HIV protease inhibitors may directly help to ease the resolution of mucosal candidiasis. "
05/01/2007 - "Highly active antiretroviral therapy including HIV protease inhibitors has led to a marked reduction of clinically relevant mucosal candidiasis. "
11/01/1999 - "On the basis of these studies we conclude that lower rates of oropharyngeal candidiasis in individuals receiving potent anti-retroviral therapy could reflect not only an improvement in the immune system but also direct inhibition of Candida secretory aspartic proteases by HIV protease inhibitors."

01/01/2014 - "HIV protease inhibitors (PIs) are highly effective in pediatric HIV treatment regimens, however, their effectiveness against malaria has been mixed, with some PIs demonstrating in vitro activity against Plasmodium falciparum. "
01/01/2009 - "Recent studies have demonstrated that human immunodeficiency virus (HIV) protease inhibitors (PIs) exert inhibitory effects on erythrocytic stages of the human-malaria parasite Plasmodium falciparum in vitro and on erythrocytic stages of the rodent-malaria parasite Plasmodium chabaudi in vivo. "
02/20/2015 - "Considering only HIV-infected children, HIV protease inhibitors avert between 278 and 1043 annual incidences of malaria per 1000 children. "
02/20/2015 - "To evaluate the benefits of HIV protease inhibitors on the health burden of recurrent malaria among children, we constructed a dynamic model of malaria transmission to both HIV-positive and HIV-negative children, parameterized by data from a recent clinical trial. "
02/01/2010 - "The aim of this study was to investigate drug interactions between HIV protease inhibitors and artemisinin drugs against malaria. "